SEC 13F Intelligence

Highline Capital Management, L.P. / RARE

Highline Capital Management, L.P.’s Ultragenyx Pharmaceutical In Position

Does Highline Capital Management, L.P. own Ultragenyx Pharmaceutical In (RARE)? Not currently — the last reported position was 295.7K shares worth $13M in Q3 2019; the fund’s latest 13F (Q4 2022) no longer reports it.

Position Value
$13M
Q3 2019
Shares
295.7K
% of Portfolio
+1.85%
Quarters Held
3
position exited

Position History RARE

Reported value by quarter
Q1 ’19: $42MQ1 ’19Q2 ’19: $25MQ2 ’19Q3 ’19: $13MQ3 ’19filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2019295.7K$13M+1.85%
Q2 2019390.5K$25M+1.81%
Q1 2019610.1K$42M+2.66%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Highline Capital Management, L.P.’s full portfolio or all institutional holders of RARE.